Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

This study has been completed.
Information provided by:
EMD Serono Identifier:
First received: March 15, 2005
Last updated: October 23, 2013
Last verified: October 2013

The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).

Condition Intervention Phase
Parkinson's Disease
Drug: Sarizotan HC1
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Resource links provided by NLM:

Further study details as provided by EMD Serono:

Enrollment: 594
Study Start Date: September 2004
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is an out-patient.
  • The subject presents with a diagnosis of idiopathic Parkinson's disease.
  • Prior therapy with all registered Parkinsonian medication is allowed.

Exclusion Criteria:

  • (For female subjects) The subject is pregnant or lactating.
  • The subject is participating in another clinical study or has done so within the past 30 days.
  • The subject has received neurosurgical intervention related to PD.
  • The subject has relevant renal impairment.
  • The subject has relevant hepatic impairment.
  • The subject is suffering from any dementia or psychiatric illness.
  • The subject has a history of allergic asthma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00105521

  Show 32 Study Locations
Sponsors and Collaborators
EMD Serono
  More Information

No publications provided Identifier: NCT00105521     History of Changes
Other Study ID Numbers: EMR 62225-019
Study First Received: March 15, 2005
Last Updated: October 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by EMD Serono:
Parkinson's Disease
Dyskinesia associated with dopaminergic treatment

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Parkinsonian Disorders
Signs and Symptoms processed this record on February 27, 2015